ライフサイエンスコーパス: cardiovascular mortality

1 arction, ischemic stroke, heart failure, and cardiovascular mortality).

2 nonfatal myocardial infarction, stroke, and cardiovascular mortality).

3 arction, ischemic stroke, heart failure, and cardiovascular mortality).

4 s associated with renal function decline and cardiovascular mortality.

5 , with significant differences for total and cardiovascular mortality.

6 LVEF was an independent predictor of 2-year cardiovascular mortality.

7 ership and subsequent all-cause mortality or cardiovascular mortality.

8 ciation between baseline characteristics and cardiovascular mortality.

9 , which is possibly driven by a reduction in cardiovascular mortality.

10 nd without prior cardiovascular disease, and cardiovascular mortality.

11 m (PE) represents the third leading cause of cardiovascular mortality.

12 t risk factor for coronary heart disease and cardiovascular mortality.

13 lung function is associated with overall and cardiovascular mortality.

14 ction, stroke, congestive heart failure, and cardiovascular mortality.

15 ical composite end point or reduce long-term cardiovascular mortality.

16 Atherosclerosis is the leading cause for cardiovascular mortality.

17 vents and significantly reduced bleeding and cardiovascular mortality.

18 ication and is associated with all-cause and cardiovascular mortality.

19 nal disease and is associated with increased cardiovascular mortality.

20 ssociation between residential greenness and cardiovascular mortality.

21 osite of time-to-first HF hospitalization or cardiovascular mortality.

22 The primary outcome was cardiovascular mortality.

23 ndition associated with an increased risk of cardiovascular mortality.

24 us thromboembolism (VTE), a leading cause of cardiovascular mortality.

25 disease, hypertension, and in some studies, cardiovascular mortality.

26 The primary outcomes were all-cause and cardiovascular mortality.

27 for positive pressure therapies for reducing cardiovascular mortality.

28 roBNP levels among PHIV were associated with cardiovascular mortality.

29 elderly men, although not significantly with cardiovascular mortality.

30 arization and conduction, is associated with cardiovascular mortality.

31 lic fatty liver disease, cardiomyopathy, and cardiovascular mortality.

32 showed little or no benefit for all-cause or cardiovascular mortality.

33 longitudinal associations with all-cause and cardiovascular mortality.

34 arization, myocardial infarction, stroke, or cardiovascular mortality.

35 with increases in lagged non-accidental and cardiovascular mortality.

36 isease (CKD) is a well-known risk factor for cardiovascular mortality.

37 ors of calcification, a major determinant of cardiovascular mortality.

38 e timing and burden of seasonal increases in cardiovascular mortality.

39 ndition associated with an increased risk of cardiovascular mortality.

40 e mortality, and the secondary end point was cardiovascular mortality.

41 n adjusted HR of 2.07 (95% CI 1.90-2.26) for cardiovascular mortality.

42 ctor 23 (FGF23), arterial calcification, and cardiovascular mortality.

43 ssociated with a lower risk of all-cause and cardiovascular mortality.

44 s), major adverse cardiac events (MACE), and cardiovascular mortality.

45 implantation, atrial fibrillation (AF), and cardiovascular mortality.

46 The primary end point was cardiovascular mortality.

47 thood may be a risk factor for all-cause and cardiovascular mortality.

48 nonfatal myocardial infarction or stroke and cardiovascular mortality.

49 with a substantial decrease in all-cause and cardiovascular mortality.

50 uent documented AF, all-cause mortality, and cardiovascular mortality.

51 biomarkers, renal dysfunction, and long-term cardiovascular mortality.

52 e of the expected benefit of such efforts on cardiovascular mortality.

53 disease and, in the case of PM(2.5), higher cardiovascular mortality.

54 The risk of cardiovascular mortality (0.5% versus 1.2%; odds ratio,

55 3), stroke (0.92, 0.67-1.25; ptrend=0.7092), cardiovascular mortality (0.73, 0.53-1.02; ptrend=0.0568

56 tality (0.73, 0.53-1.02; ptrend=0.0568), non-cardiovascular mortality (0.84, 0.68-1.04; ptrend =0.003

57 90, 95% CI 0.82-0.99; p=0.033), a 13% RRR in cardiovascular mortality (0.87, 0.79-0.96; p=0.007), and

58 -1.11 and either LPA SNP 1.10, 0.92-1.31) or cardiovascular mortality (0.99, 0.81-1.2 and 1.13, 0.90-

59 (95% CIs) were 0.74 (0.64-0.86; P<0.001) for cardiovascular mortality; 0.73 (0.65-0.82; P<0.001) for

60 (hazard ratio [HR] 1.19, 95% CI 1.10-1.28), cardiovascular mortality (1.24, 1.10-1.39), and respirat

61 l-cause mortality (1.96 [95% CI 1.80-2.14]), cardiovascular mortality (1.93 [1.63-2.29]) and cancer m

62 th low LVEF had higher crude rates of 2-year cardiovascular mortality (19.8% versus 12.0%, P<0.0001)

63 e NT-proBNP thresholds reduced all-cause and cardiovascular mortality (2 of 4 studies) and the compos

64 difference, 4.1% [95% CI, -17.2% to 25.3%]), cardiovascular mortality (5.0% vs 7.4%; adjusted differe

65 (8.0% versus 9.8%, respectively; P=0.54) or cardiovascular mortality (6.5% versus 9.1%; P=0.40).

66 Trends in cardiovascular mortality across Europe demonstrate signi

67 rot) and PMI(UD) were associated with 5-year cardiovascular mortality (adjusted hazard ratio [HR]: 2.

68 0.12; p = 0.001) and a ~10-fold reduction in cardiovascular mortality (adjusted hazard ratio: 0.10; p

69 ssociated with increased 2-year risk of both cardiovascular mortality (adjusted HR per 10% decrease i

70 te the associations of PN with all-cause and cardiovascular mortality after adjustment for demographi

71 0.37) and predicted all-cause mortality and cardiovascular mortality after adjustment for establishe

72 ) was associated with a consistent hazard of cardiovascular mortality after both PCI and CABG (p(inte

73 ersely, PMI(UD) was strongly associated with cardiovascular mortality after CABG (adjusted HR: 11.94;

74 cause (aHR, 1.45 [1.09-1.94]; P = 0.012) and cardiovascular mortality (aHR, 1.49 [1.00-2.22]; P = 0.0

75 sed aHR for the secondary outcome, MACCE, or cardiovascular mortality (aHR, 1.92 [1.12-3.30]; P = 0.0

76 olesterol efflux capacity is associated with cardiovascular mortality, all-cause mortality, and graft

77 valsartan was associated with a reduction in cardiovascular mortality, all-cause mortality, and hospi

78 Out-of-sample prediction of cardiovascular mortality among adults 65 years and older

79 Although pCAD was not associated with cardiovascular mortality among all individuals (hazard r

80 ic embolic event, myocardial infarction, and cardiovascular mortality, analysed by intention to treat

81 actors associated with increased longer-term cardiovascular mortality and (2) incremental prognostic

82 ociated with a 0.27% (0.11-0.44) increase in cardiovascular mortality and a 0.56% (0.24-0.87) increas

83 with a 0.47% (95% CI 0.34-0.61) increase in cardiovascular mortality and a 0.57% (0.28-0.86) increas

84 ssociated with reduced risk of all-cause and cardiovascular mortality and CVD events, with greater ab

85 epression and anxiety also feature increased cardiovascular mortality and decreased heart-rate variab

86 with enalapril, sacubitril-valsartan reduces cardiovascular mortality and heart failure hospitalizati

87 lic BP <140 mm Hg) decreased MACE, including cardiovascular mortality and heart failure.

88 y, or supplemental calcium intake levels and cardiovascular mortality and highly inconsistent dose-re

89 e echocardiography and a composite endpoint (cardiovascular mortality and hospitalization) were evalu

90 paired baroreflex sensitivity (BRS) predicts cardiovascular mortality and is prevalent in long-term d

91 ships were equally observed when considering cardiovascular mortality and MACEs at 90 days (adjHR: 2.

92 ated with an 86% and a 38% increased risk of cardiovascular mortality and major cardiovascular events

93 ion, AKI associates with an elevated risk of cardiovascular mortality and major cardiovascular events

94 associated with an increase in all-cause and cardiovascular mortality and might both be therapeutic t

95 Aortic stenosis (AS) contributes to cardiovascular mortality and morbidity but disease mecha

96 from clinical practice, we aimed to compare cardiovascular mortality and morbidity in new users of S

97 sartan provides reasonable value in reducing cardiovascular mortality and morbidity in patients with

98 tudy confirms that exercise-based CR reduces cardiovascular mortality and provides important data sho

99 Outcomes were long-term all-cause and cardiovascular mortality and recurrent MI.

100 Similar associations were found for rates of cardiovascular mortality and rehospitalization.

101 This analysis also suggests that risk of cardiovascular mortality and stent thrombosis might be l

102 ctrocardiogram significantly associates with cardiovascular mortality and sudden cardiac death indepe

103 Benefits appear to be maximum for both non-cardiovascular mortality and total mortality at three to

104 ause mortality, 0.80 (95% CI, 0.78-0.81) for cardiovascular mortality, and 0.92 (95% CI, 0.91-0.94) f

105 use mortality, 1.29 (95% CI: 0.83, 2.00) for cardiovascular mortality, and 1.10 (95% CI: 0.88, 1.37)

106 ates of major adverse cardiovascular events, cardiovascular mortality, and all-cause mortality accord

107 e-point major adverse cardiovascular events, cardiovascular mortality, and all-cause mortality risk,

108 ncluding stroke, coronary revascularization, cardiovascular mortality, and all-cause mortality were a

109 , myocardial infarction, and heart failure), cardiovascular mortality, and all-cause mortality.

110 ischemic stroke, coronary revascularization, cardiovascular mortality, and all-cause mortality.

111 with increased risk of all-cause mortality, cardiovascular mortality, and graft failure and, of all

112 e studied outcomes were all-cause mortality, cardiovascular mortality, and hospitalization for HF.

113 Observed rates of all-cause mortality, cardiovascular mortality, and myocardial infarction in 2

114 y disease (PAD) is associated with increased cardiovascular mortality, and PAD risk factors overlap w

115 al infarction, cardiovascular mortality, non-cardiovascular mortality, and total mortality in the mod

116 fatal strokes, cardiovascular mortality, non-cardiovascular mortality, and total mortality.

117 receptor agonists has beneficial effects on cardiovascular, mortality, and kidney outcomes in patien

118 Decreased inflammation and cardiovascular mortality are evident in patients with en

119 Geographic variations in cardiovascular mortality are substantial, but descriptio

120 The decreasing association with cardiovascular mortality as the time since last use of c

121 , multivariate models revealed all-cause and cardiovascular mortality associated with age, aortic PWV

122 ular volumes and hypertrophy was greater and cardiovascular mortality at 3-year follow-up was lower (

123 Cardiovascular mortality at 90 days was 0% among T2MI201

124 e no significant differences in all-cause or cardiovascular mortality between groups.

125 We used Cox regression analysis to compare cardiovascular mortality between participants with versu

126 There is a growing disparity in cardiovascular mortality between Western and Eastern Eur

127 pective estimation of influenza-attributable cardiovascular mortality burden combined with accurate a

128 mula: see text]) exposure is associated with cardiovascular mortality, but little is known about the

129 ion was causally associated with low risk of cardiovascular mortality, but not with low all-cause mor

130 and rs3798220) with all-cause mortality and cardiovascular mortality by Cox regression analysis and

131 The persistent high (cardiovascular) mortality calls for further intensificat

132 cident clinical events (all-cause mortality, cardiovascular mortality, cancer mortality, cardiovascul

133 ite of first cardiovascular event, including cardiovascular mortality, cardiovascular morbidity (non-

134 LVNC patients had a similar risk of cardiovascular mortality compared with a dilated cardiom

135 ground: Sacubitril-valsartan therapy reduces cardiovascular mortality compared with enalapril therapy

136 ed with increased risks of heart failure and cardiovascular mortality compared with tamoxifen.

137 outcome of heart failure hospitalization or cardiovascular mortality compared with those without a h

138 ated with reduced cardiovascular disease and cardiovascular mortality compared with use of other gluc

139 icial effects on hemoglobin A1c, weight, and cardiovascular mortality (compared with sulfonylureas).

140 estricted the analyses to studies evaluating cardiovascular mortality, dog ownership conferred a 31%

141 nted for 83.0% (73363 deaths) of nonpandemic cardiovascular mortality during influenza seasons, seaso

142 also independently associated with MACE and cardiovascular mortality during short-time (3 months) fo

143 Adjusted cardiovascular mortality estimates at 10 years were 17%,

144 concentration was associated with increased cardiovascular mortality (first tertile, 11.5; second te

145 -dependent interaction between all-cause and cardiovascular mortality following VIV TAVR was reported

146 We aimed to compare cardiovascular mortality for different age groups in the

147 Although cardiovascular mortality has declined, the devastating i

148 Cardiovascular mortality has decreased in recent decades

149 Cardiovascular mortality has decreased over the past 5 d

150 lopidogrel, ticagrelor significantly reduced cardiovascular mortality (hazard ratio [HR], 0.82 [95% C

151 that efflux capacity was not associated with cardiovascular mortality (hazard ratio [HR], 0.89; 95% c

152 (hazard ratio, 1.16 [95% CI, 1.01-1.33]) and cardiovascular mortality (hazard ratio, 1.49 [95% CI, 1.

153 1.85; P=0.006 per SD decrease) and increased cardiovascular mortality (hazard ratio, 1.55; 95% confid

154 , 1.917 [95% CI, 1.207-3.045], P=0.006), and cardiovascular mortality (hazard ratio, 2.008 [95% CI, 1

155 nificantly associated with increased risk of cardiovascular mortality (hazard ratio, 2.99; 95% confid

156 fidence interval: 1.2 to 2.7; p = 0.004) and cardiovascular mortality (hazard ratio: 2.7; 95% confide

157 mental temperature with all-cause mortality, cardiovascular mortality, heat-related mortality, and mo

158 d hazard ratio 0.85 [95% CI, 0.75-0.96]) and cardiovascular mortality/HF hospitalization (0.87 [0.77-

159 ced CKD with HFpEF (death: 0.88 [0.77-1.02], cardiovascular mortality/HF hospitalization: 1.05 [0.90-

160 0-1.23]) or HFmrEF (death: 0.95 [0.79-1.14], cardiovascular mortality/HF hospitalization: 1.09 [0.90-

161 rtic aneurysm (AAA) is an important cause of cardiovascular mortality; however, its genetic determina

162 omeostasis is the third most common cause of cardiovascular mortality; however, key molecular determi

163 social integration is associated with lower cardiovascular mortality; however, whether it is associa

164 bitors was associated with decreased risk of cardiovascular mortality (HR 0.53 [95% CI 0.40-0.71]), m

165 lure (HR = 1.69, 95% CI: 0.79, 3.62) but not cardiovascular mortality (HR = 0.87, 95% CI: 0.49, 1.54)

166 tment hsCRP concentrations less than 2 mg/L, cardiovascular mortality (HR(adj)=0.69, 95% CI 0.56-0.85

167 Surgery also was associated with lower cardiovascular mortality (HR, 0.53 [CI, 0.34 to 0.84]) a

168 e 4 primary fatty acids were associated with cardiovascular mortality (HR, 0.92-1.05 for each standar

169 mortality (HR, 1.11 [CI, 0.89 to 1.46]), or cardiovascular mortality (HR, 1.04 [CI, 0.65 to 1.66]).

170 .16]; and HR,1.21 [95% CI,1.15 to 1.27]) and cardiovascular mortality (HR, 1.05 [95% CI,1.00 to 1.10]

171 ard ratio [HR], 1.49 [CI, 1.15 to 1.94]) and cardiovascular mortality (HR, 1.66 [CI, 1.07 to 2.57]) i

172 dence interval [CI], 1.21-2.85; P=0.004) and cardiovascular mortality (HR, 1.70; 95% CI, 1.06-2.89; P

173 mortality (HR, 1.33 [CI, 1.07 to 1.67]), and cardiovascular mortality (HR, 2.09 [CI, 1.23 to 4.48]);

174 CI, 1.16-3.22; HR, 1.84; 95% CI, 1.02-3.31), cardiovascular mortality (HR, 4.36; 95% CI, 1.37-13.83;

175 mortality (HR: 1.17; 95% CI: 1.12-1.22), and cardiovascular mortality (HR: 1.17; 95% CI: 1.07-1.28).

176 life-threatening arrhythmic events (LAE) and cardiovascular mortality; identify risk factors associat

177 velop region-specific estimates of premature cardiovascular mortality in 2025 based on various scenar

178 of newborns and is associated with increased cardiovascular mortality in adulthood.

179 sity were strongly associated with increased cardiovascular mortality in adulthood.

180 gest that hemodiafiltration (HDF) may reduce cardiovascular mortality in adults, but data for childre

181 ight metalworking fluids have been linked to cardiovascular mortality in analyses using binary exposu

182 robust evidence of higher nonaccidental and cardiovascular mortality in association with short-term

183 greenness was linked to a ~ 10% decrease in cardiovascular mortality in both adults free of AMI and

184 in native chronic kidney disease as well as cardiovascular mortality in chronic kidney disease more

185 f offspring was not associated with total or cardiovascular mortality in fathers.

186 After 8+/-6 years, cardiovascular mortality in FG+ probands with HCM was si

187 ratio [RR], 0.90 [95% CI, 0.85 to 0.95]) and cardiovascular mortality in hypertensive participants (R

188 ficacy of statin-based therapies in reducing cardiovascular mortality in individuals with CKD seems t

189 diac troponin is an independent predictor of cardiovascular mortality in individuals without symptoms

190 th substantially increased risk of total and cardiovascular mortality in Korean adults.

191 ndently associated with higher all-cause and cardiovascular mortality in multivariable analyses.

192 ntly associated with increased all-cause and cardiovascular mortality in patients treated with PCI.

193 myocardial strain, contributes to increased cardiovascular mortality in patients with CKD.

194 c events have been associated with increased cardiovascular mortality in patients with diabetes, whic

195 zation dynamics, is strongly associated with cardiovascular mortality in patients with heart failure.

196 Results were also null for cardiovascular mortality in the 2 external cohorts (eg,

197 onference to further explore these trends in cardiovascular mortality in the context of what has come

198 h improved insulin sensitivity and decreased cardiovascular mortality in the general population, but

199 Considering the extraordinarily high rate of cardiovascular mortality in the hemodialysis population,

200 Survival free of all-cause and cardiovascular mortality in the transfemoral patients fr

201 (lag 2 and 0-5 day) and Arizona (lag 3), for cardiovascular mortality in the United States (lag 2) an

202 with altered cardiac structure and increased cardiovascular mortality in the young.

203 Hypoglycemia is associated with increased cardiovascular mortality in trials of intensive therapy

204 son-years; HR, 1.86 [95% CI, 1.14-3.03]) and cardiovascular mortality (incidence rate, 9.5 versus 4.7

205 The risk of cardiovascular mortality increased with increasing durat

206 PV distensibility also predicted cardiovascular mortality independent of peak VO2 in HF p

207 d socioeconomic factors were associated with cardiovascular mortality, independent of each other.

208 Cardiovascular mortality is high in rural areas.

209 Cardiovascular mortality is the leading cause of death i

210 Background Cardiovascular mortality is the leading contributor to t

211 In the United States, regional variation in cardiovascular mortality is well-known but county-level

212 r patterns of associations were observed for cardiovascular mortality.Lower grip strength and excess

213 Cardiovascular outcomes investigated were cardiovascular mortality, major adverse cardiovascular e

214 isk (RR) for the association between AKI and cardiovascular mortality, major cardiovascular events, a

215 the effects of PM(2.5) on AMI incidence and cardiovascular mortality may be 10% to 27% higher than w

216 e associated with incident events, including cardiovascular mortality.Measurements and Main Results:

217 etermined by the census tract-level rates of cardiovascular mortality/morbidity events.

218 tality, major adverse cardiovascular events (cardiovascular mortality, myocardial infarction, and isc

219 The primary endpoints were cardiovascular mortality, myocardial infarction, and str

220 nd ARBs with respect to all-cause mortality, cardiovascular mortality, myocardial infarction, stroke,

221 ial infarction, fatal and non-fatal strokes, cardiovascular mortality, non-cardiovascular mortality,

222 rdiovascular disease, myocardial infarction, cardiovascular mortality, non-cardiovascular mortality,

223 imary outcome including, but not limited to, cardiovascular mortality, non-fatal myocardial infarctio

224 dverse cardiovascular event primary outcome (cardiovascular mortality, non-fatal myocardial infarctio

225 Outcomes of interest were total mortality, cardiovascular mortality, noncardiovascular mortality, c

226 ry cardiovascular outcome was a composite of cardiovascular mortality, nonfatal myocardial infarction

227 s in prognosis (composite end point included cardiovascular mortality, nonfatal reinfarction, coronar

228 Cardiovascular mortality occurred in 10 LGE-positive ver

229 terval, 0.29-0.77; P=0.003), a lower risk of cardiovascular mortality (odds ratio =0.41, 95% confiden

230 preserved CFR and maximal MBF had the lowest cardiovascular mortality of 0.4% (95 CI, 0.3-0.6) per ye

231 eserved CFR but impaired maximal MBF had low cardiovascular mortality of 0.9% (95% CI, 0.6-1.6) per y

232 ality that was consistent across approaches: cardiovascular mortality of 1.07 (95% CI: 1.03-1.11) per

233 reported 30-day all-cause mortality of 2.2%, cardiovascular mortality of 1.1%, stroke of 1.4%, major

234 ut preserved maximal MBF had an intermediate cardiovascular mortality of 1.7% (95% CI, 1.3-2.1) per y

235 t impairment of CFR and maximal MBF had high cardiovascular mortality of 3.3% (95% CI, 2.9-3.7) per y

236 lationship could reinforce the prediction of cardiovascular mortality or events over classical CVRF o

237 benefit of the interventions on all-cause or cardiovascular mortality or morbidity (4 trials [n = 513

238 nfidence interval [CI], 0.79-1.5; P=0.53) or cardiovascular mortality (OR, 1.03; 95% CI, 0.72-1.46; P

239 imary composite outcome (HF hospitalization, cardiovascular mortality, or aborted cardiac arrest), it

240 o significant effect on all-cause mortality, cardiovascular mortality, or stroke; however, there is a

241 all-cause mortality) and secondary (MACCE or cardiovascular mortality) outcome.

242 Great progress has been made in reducing cardiovascular mortality over the past 50 years.

243 ion, nonfatal stroke, and >30% reductions in cardiovascular mortality, overall mortality, and heart f

244 annose and glycocholate were associated with cardiovascular mortality (P < 1.23 x 10(-4)), but predic

245 l; 18.2%; p for trend <0.001) and with lower cardiovascular mortality (p = 0.001), but not with lower

246 ence was correlated year to year with excess cardiovascular mortality (Pearson correlation coefficien

247 OR 0.62, 95% CI 0.55 to 0.69, p < 0.001) and cardiovascular mortality (POR 0.50, 95% CI 0.35 to 0.71,

248 ed with a decrease in HF hospitalization and cardiovascular mortality (primary endpoint) in patients

249 The lowest cardiovascular mortality rates were found in the countie

250 mortality (RD, 0.004 [CI, -0.010 to 0.017]), cardiovascular mortality (RD, 0.001 [CI, -0.011 to 0.013

251 iscounted price of $10311) and $483800 if no cardiovascular mortality reduction emerges.

252 to MED has a consistent beneficial effect on cardiovascular mortality regardless of age.

253 associated with higher risk of all-cause and cardiovascular mortality regardless of BMI levels, and t

254 ity and major cardiovascular events (MACEs) (cardiovascular mortality, reinfarction, or ischemic stro

255 Overall, CR led to a reduction in cardiovascular mortality (relative risk: 0.74; 95% confi

256 Cardiovascular mortality remained the main cause of deat

257 azard ratio =2.49 and 2.94 for all-cause and cardiovascular mortality, respectively).

258 dence interval, 1.06-1.17) for all-cause and cardiovascular mortality, respectively.

259 CI = 1.24-5.40) higher risk of all-cause and cardiovascular mortality, respectively.

260 In multivariable analysis, the cardiovascular mortality risk gradient across the 4 conc

261 y, but not femoral atherosclerosis, and with cardiovascular mortality risk.

262 r clot structure had increased all-cause and cardiovascular mortality risks (log rank P=0.004 and P=0

263 e [ARD], -0.40% [95% CI, -0.64% to -0.17%]), cardiovascular mortality (RR, 0.69 [95% CI, 0.54 to 0.88

264 use mortality (RR, 0.85; 95% CI, 0.70-1.03), cardiovascular mortality (RR, 0.84; 95% CI, 0.59-1.18),

265 e mortality (RR, 0.95 [CI, 0.89 to 1.01]) or cardiovascular mortality (RR, 0.97 [CI, 0.85 to 1.10]).

266 ACE (RR: 0.71; 95% CI: 0.60 to 0.84), 33% in cardiovascular mortality (RR: 0.67; 95% CI: 0.45 to 0.98

267 ted case reports that reported all-cause and cardiovascular mortality, RRT, kidney function, BP, and

268 Successful device implantation free of cardiovascular mortality, stroke, and device malfunction

269 to be a powerful predictor for all-cause and cardiovascular mortality, stroke, coronary artery diseas

270 (major adverse cardiovascular events [MACE], cardiovascular mortality, stroke, myocardial infarction,

271 with increased risk of all-cause mortality, cardiovascular mortality, stroke, or myocardial infarcti

272 CFR was a stronger predictor of cardiovascular mortality than maximal MBF beyond traditi

273 CFR is a stronger predictor of cardiovascular mortality than maximal MBF.

274 ype 2 MI have higher long-term all-cause and cardiovascular mortality than those who experience type

275 Mothers had increased risk of total and cardiovascular mortality that was consistent across appr

276 For cardiovascular mortality, the differences were similar f

277 In the pooled cohort for cardiovascular mortality, the HR was 1.00 (95% CI, 0.92-

278 These associations were similar for cardiovascular mortality (unadjusted HR: 0.83; 95% CI: 0

279 included 30-day all-cause mortality, 30-day cardiovascular mortality, unscheduled readmission, lengt

280 w-up of 2.9 years, the pooled event rate for cardiovascular mortality was 1.92 (95% CI, 1.54-2.30) pe

281 Cardiovascular mortality was 12% (n = 53) in the biomark

282 The 3-year all-cause mortality was 42.0% and cardiovascular mortality was 17.5%.

283 LVEF (<50%) at baseline, and 2-year risk of cardiovascular mortality was compared using Kaplan-Meier

284 ction=0.062), whereas the benefit of CABG on cardiovascular mortality was consistent over all ages (P

285 Cardiovascular mortality was lower for metformin versus

286 o 1.50]), but the association between PN and cardiovascular mortality was not statistically significa

287 In contrast, cardiovascular mortality was not statistically significa

288 Cardiovascular mortality was numerically higher in patie

289 PAR as the reference, crude hazard ratio for cardiovascular mortality were 1.58 (95% CI 1.16-2.16), 1

290 Crude and hazard ratios for all-cause and cardiovascular mortality were analyzed at 90 days and 1

291 s between time-varying PRAs and all-cause or cardiovascular mortality were assessed using Cox proport

292 h risks of long-term all-cause mortality and cardiovascular mortality were evaluated with the use of

293 ascular adverse events and treatment-related cardiovascular mortality were included.

294 ereas the associations with incident CVD and cardiovascular mortality were no longer significant.

295 Adjusted hazard ratios (95% CIs) for cardiovascular mortality were significantly elevated amo

296 o kidney disease, adjusted hazard ratios for cardiovascular mortality were significantly higher among

297 Unexpectedly, lower odds of cardiovascular mortality were suggested with greater con

298 rse efficacy events, particularly stroke and cardiovascular mortality, whereas severe bleedings were

299 positively associated with AMI incidence and cardiovascular mortality with all four methods.

300 he prespecified primary efficacy outcome was cardiovascular mortality within 30 days, and the primary